Oppenheimer Maintains Outperform on Sutro Biopharma, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson has maintained an Outperform rating on Sutro Biopharma (NASDAQ:STRO) and has also maintained a price target of $10 for the company's stock.

March 27, 2024 | 11:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Jay Olson reaffirmed an Outperform rating on Sutro Biopharma, with a steady price target of $10.
The reaffirmation of an Outperform rating and a $10 price target by a reputable analyst like Jay Olson from Oppenheimer could instill confidence among investors and potentially lead to a positive short-term impact on Sutro Biopharma's stock price. Analyst ratings, especially from well-regarded financial institutions, can significantly influence investor sentiment and stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100